Literature DB >> 1827704

Diagnosis and laparoscopic grading of acute salpingitis.

D E Soper1.   

Abstract

Pelvic inflammatory disease continues to be a major cause of morbidity in women of reproductive age. Findings of bilateral adnexal tenderness and signs of a lower genital tract infection (mucopus, or leukorrhea, or both) should prompt clinicians to consider the diagnosis of salpingitis in this group of women. Additional signs of infection, such as elevated temperature, palpable adnexal complex, leukocytosis, elevated erythrocyte sedimentation rate, or c-reactive protein, and positive tests for either Neisseria gonorrhoeae or Chlamydia trachomatis will improve the overall specificity of the clinical diagnosis. Endometrial biopsy offers an acceptable approach to documenting objectively inflammation of the upper genital tract. Diagnostic laparoscopy should be considered in all patients but may be especially helpful for those patients in whom a diagnosis is unclear. A laparoscopic grading system based primarily on tubal mobility and inflammation can be useful in predicting duration of in-hospital therapy and future tubal factor infertility.

Entities:  

Mesh:

Year:  1991        PMID: 1827704     DOI: 10.1016/0002-9378(91)91474-b

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Laparoscopic approach to acute abdomen from the Consensus Development Conference of the Società Italiana di Chirurgia Endoscopica e nuove tecnologie (SICE), Associazione Chirurghi Ospedalieri Italiani (ACOI), Società Italiana di Chirurgia (SIC), Società Italiana di Chirurgia d'Urgenza e del Trauma (SICUT), Società Italiana di Chirurgia nell'Ospedalità Privata (SICOP), and the European Association for Endoscopic Surgery (EAES).

Authors:  Ferdinando Agresta; Luca Ansaloni; Gian Luca Baiocchi; Carlo Bergamini; Fabio Cesare Campanile; Michele Carlucci; Giafranco Cocorullo; Alessio Corradi; Boris Franzato; Massimo Lupo; Vincenzo Mandalà; Antonino Mirabella; Graziano Pernazza; Micaela Piccoli; Carlo Staudacher; Nereo Vettoretto; Mauro Zago; Emanuele Lettieri; Anna Levati; Domenico Pietrini; Mariano Scaglione; Salvatore De Masi; Giuseppe De Placido; Marsilio Francucci; Monica Rasi; Abe Fingerhut; Selman Uranüs; Silvio Garattini
Journal:  Surg Endosc       Date:  2012-06-27       Impact factor: 4.584

2.  The iron-repressed, AraC-like regulator MpeR activates expression of fetA in Neisseria gonorrhoeae.

Authors:  Aimee Hollander; Alexandra Dubon Mercante; William M Shafer; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2011-09-26       Impact factor: 3.441

Review 3.  MDCT of pelvic inflammatory disease: a review of the pathophysiology, gamut of imaging findings, and treatment.

Authors:  James Spain; Matthew Rheinboldt
Journal:  Emerg Radiol       Date:  2016-09-19

Review 4.  Laparoscopy for abdominal emergencies: evidence-based guidelines of the European Association for Endoscopic Surgery.

Authors:  S Sauerland; F Agresta; R Bergamaschi; G Borzellino; A Budzynski; G Champault; A Fingerhut; A Isla; M Johansson; P Lundorff; B Navez; S Saad; E A M Neugebauer
Journal:  Surg Endosc       Date:  2005-10-24       Impact factor: 3.453

5.  Accuracy of five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease.

Authors:  Hernando Gaitán; Edith Angel; Rodrigo Diaz; Arturo Parada; Lilia Sanchez; Cara Vargas
Journal:  Infect Dis Obstet Gynecol       Date:  2002

6.  Antibiotic therapy for pelvic inflammatory disease.

Authors:  Ricardo F Savaris; Daniele G Fuhrich; Jackson Maissiat; Rui V Duarte; Jonathan Ross
Journal:  Cochrane Database Syst Rev       Date:  2020-08-20

7.  Diagnostic evaluation of pelvic inflammatory disease.

Authors:  J F Peipert; D E Soper
Journal:  Infect Dis Obstet Gynecol       Date:  1994

8.  Laparoscopic diagnosis and treatment in gynecologic emergencies.

Authors:  Salvador Navarrete Aulestia; Héctor Cantele; José Luis Leyba; Manuel Navarrete; Salvador Navarrete Llopla
Journal:  JSLS       Date:  2003 Jul-Sep       Impact factor: 2.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.